Literature DB >> 20582554

Perioperative complications with rhBMP-2 in transforaminal lumbar interbody fusion.

Kirk Owens1, Steven D Glassman, Jennifer M Howard, Mladen Djurasovic, Jonathan L Witten, Leah Y Carreon.   

Abstract

Bone morphogenetic protein (BMP) is commonly used as an ICBG substitute for transforaminal lumbar interbody spine fusion (TLIF). However, multiple recent reports have raised concerns regarding a substantial incidence of perioperative radiculopathy. Also, given the serious complications reported with anterior cervical BMP use, risks related to swelling and edema with TLIF need to be clarified. As TLIF related complications with rhBMP-2 have generally been reported in small series or isolated cases, without a clear denominator, actual complication rates are largely unknown. The purpose this study is to characterize perioperative complications and complication rates in a large consecutive series of TLIF procedures with rhBMP-2. We reviewed inpatient and outpatient medical records for a consecutive series of 204 patients [113 females, 91 males, mean age 49.3 (22-79) years] who underwent TLIF using rhBMP-2 between 2003 and 2007. Complications observed within a 3-month perioperative interval were categorized as to etiology and severity. Wound problems were delineated as wound infection, hematoma/seroma or persistent drainage/superficial dehiscence. Neurologic deficits and radiculopathies were analyzed to determine the presence of a clear etiology (screw misplacement) and identify any potential relationship to rhBMP-2 usage. Complications were observed in 47 of 204 patients (21.6%) during the 3-month perioperative period. Major complications occurred in 13 patients (6.4%) and minor complications in 34 patients (16.7%). New or more severe postoperative neurologic complaints were noted in 13 patients (6.4%), 6 of whom required additional surgery. These cases included one malpositioned pedicle screw and one epidural hematoma. In four patients (2.0%), localized seroma/hematoma in the area of the foramen caused neural compression, and required revision. In one additional patient, vertebral osteolysis caused foraminal narrowing and radiculopathy, but resolved without further surgery. Persistent radiculopathy without clear etiology on imaging studies was seen in six patients. Wound related problems were seen in six patients (2.9%), distributed as wound infection (3), hematoma/seroma (1) and persistent drainage/dehiscence (2). Overall, this study demonstrates a modest complication rate for TLIF using rhBMP-2. While perioperative complications which appeared specific to BMP usage were noted, they occurred infrequently. It will be necessary to weigh this incidence of complications against the complication rate associated with ICBG harvest and any differential benefit in obtaining a solid arthrodesis.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20582554      PMCID: PMC3065615          DOI: 10.1007/s00586-010-1494-7

Source DB:  PubMed          Journal:  Eur Spine J        ISSN: 0940-6719            Impact factor:   3.134


  34 in total

1.  Anterior lumbar interbody fusion using rhBMP-2 with tapered interbody cages.

Authors:  J Kenneth Burkus; Matthew F Gornet; Curtis A Dickman; Thomas A Zdeblick
Journal:  J Spinal Disord Tech       Date:  2002-10

2.  Transforaminal lumbar interbody fusion: a safe technique with satisfactory three to five year results.

Authors:  Lars Hackenberg; Henry Halm; Viola Bullmann; Volker Vieth; Marc Schneider; Ulf Liljenqvist
Journal:  Eur Spine J       Date:  2005-01-26       Impact factor: 3.134

3.  Is INFUSE bone graft superior to autograft bone? An integrated analysis of clinical trials using the LT-CAGE lumbar tapered fusion device.

Authors:  J Kenneth Burkus; Stephen E Heim; Matthew F Gornet; Thomas A Zdeblick
Journal:  J Spinal Disord Tech       Date:  2003-04

4.  Adverse effects associated with high-dose recombinant human bone morphogenetic protein-2 use in anterior cervical spine fusion.

Authors:  Lisa B E Shields; George H Raque; Steven D Glassman; Mitchell Campbell; Todd Vitaz; John Harpring; Christopher B Shields
Journal:  Spine (Phila Pa 1976)       Date:  2006-03-01       Impact factor: 3.468

5.  Allograft implants for posterior lumbar interbody fusion: results comparing cylindrical dowels and impacted wedges.

Authors:  Bryan Barnes; Gerald E Rodts; Regis W Haid; Brian R Subach; Mark R McLaughlin
Journal:  Neurosurgery       Date:  2002-11       Impact factor: 4.654

6.  Complications in lumbar fusion surgery for chronic low back pain: comparison of three surgical techniques used in a prospective randomized study. A report from the Swedish Lumbar Spine Study Group.

Authors:  Peter Fritzell; Olle Hägg; Anders Nordwall
Journal:  Eur Spine J       Date:  2003-02-14       Impact factor: 3.134

7.  Safety of transforaminal lumbar interbody fusion and intervertebral recombinant human bone morphogenetic protein-2.

Authors:  Alan T Villavicencio; Sigita Burneikiene; E Lee Nelson; Ketan R Bulsara; Mark Favors; Jeffrey Thramann
Journal:  J Neurosurg Spine       Date:  2005-12

8.  Transforaminal lumbar interbody fusion: clinical and radiographic results and complications in 100 consecutive patients.

Authors:  Benjamin K Potter; Brett A Freedman; Eric G Verwiebe; Jordan M Hall; David W Polly; Timothy R Kuklo
Journal:  J Spinal Disord Tech       Date:  2005-08

9.  Longitudinal element size effect on load sharing, internal loads, and fatigue life of tri-level spinal implant constructs.

Authors:  R C Duffield; W L Carson; L Y Chen; B Voth
Journal:  Spine (Phila Pa 1976)       Date:  1993-09-15       Impact factor: 3.468

10.  Functional outcomes of instrumented posterior lumbar interbody fusion in active-duty US servicemen: a comparison with nonoperative management.

Authors:  R W Molinari; T Gerlinger
Journal:  Spine J       Date:  2001 May-Jun       Impact factor: 4.166

View more
  25 in total

1.  2011 AOA Symposium: Tissue Engineering and Tissue Regeneration: AOA critical issues.

Authors:  Scott A Rodeo; Scott D Boden; Martha M Murray; Thomas A Einhorn
Journal:  J Bone Joint Surg Am       Date:  2013-08-07       Impact factor: 5.284

Review 2.  What's new in spine surgery.

Authors:  Keith H Bridwell; Paul A Anderson; Scott D Boden; Alexander R Vaccaro; Jeffrey C Wang
Journal:  J Bone Joint Surg Am       Date:  2011-08-17       Impact factor: 5.284

3.  Trends analysis of rhBMP utilization in single-level posterior lumbar fusion (PLF) in the United States.

Authors:  Lifeng Lao; Jeremiah R Cohen; Elizabeth L Lord; Zorica Buser; Jeffrey C Wang
Journal:  Eur Spine J       Date:  2015-05-24       Impact factor: 3.134

4.  Comparison of the use of rhBMP-7 versus iliac crest autograft in single-level lumbar fusion: a meta-analysis of randomized controlled trials.

Authors:  Fubiao Ye; Zhiyuan Zeng; Jianru Wang; Hui Liu; Hua Wang; Zhaomin Zheng
Journal:  J Bone Miner Metab       Date:  2017-03-24       Impact factor: 2.626

5.  Lumbar interbody fusion with utilization of recombinant human bone morphogenetic protein: a retrospective real-life study about 277 patients.

Authors:  Stéphane Litrico; Tristan Langlais; Florent Pennes; Antoine Gennari; Philippe Paquis
Journal:  Neurosurg Rev       Date:  2017-03-10       Impact factor: 3.042

6.  Use of bone morphogenetic protein among patients undergoing fusion for degenerative diagnoses in the United States, 2002 to 2012.

Authors:  Brook I Martin; Jon D Lurie; Anna N A Tosteson; Richard A Deyo; Farrokh R Farrokhi; Sohail K Mirza
Journal:  Spine J       Date:  2014-12-15       Impact factor: 4.166

Review 7.  A Review of the Clinical Side Effects of Bone Morphogenetic Protein-2.

Authors:  Aaron W James; Gregory LaChaud; Jia Shen; Greg Asatrian; Vi Nguyen; Xinli Zhang; Kang Ting; Chia Soo
Journal:  Tissue Eng Part B Rev       Date:  2016-04-19       Impact factor: 6.389

Review 8.  Review of the Applications of Biomedical Compositions Containing Hydroxyapatite and Collagen Modified by Bioactive Components.

Authors:  Agnieszka Sobczak-Kupiec; Anna Drabczyk; Wioletta Florkiewicz; Magdalena Głąb; Sonia Kudłacik-Kramarczyk; Dagmara Słota; Agnieszka Tomala; Bożena Tyliszczak
Journal:  Materials (Basel)       Date:  2021-04-21       Impact factor: 3.623

9.  BMP2-induced inflammation can be suppressed by the osteoinductive growth factor NELL-1.

Authors:  Jia Shen; Aaron W James; Janette N Zara; Greg Asatrian; Kevork Khadarian; James B Zhang; Stephanie Ho; Hyun Ju Kim; Kang Ting; Chia Soo
Journal:  Tissue Eng Part A       Date:  2013-07-17       Impact factor: 3.845

10.  The effects of a single intravenous injection of novel activin A/BMP-2 (AB204) on toxicity and the respiratory and central nervous systems.

Authors:  Byung-Hak Yoon; Jae Hyup Lee; Kyuheum Na; Chihoon Ahn; Jongho Cho; Hyun Chan Ahn; Jungyoun Choi; Hyosun Oh; Byong Moon Kim; Senyon Choe
Journal:  Drug Chem Toxicol       Date:  2015-10-07       Impact factor: 3.356

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.